Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $100000.0.

  • Lyra Therapeutics' Depreciation & Amortization (CF) rose 40000.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $608000.0, marking a year-over-year increase of 3131.75%. This contributed to the annual value of $500000.0 for FY2024, which is 6666.67% up from last year.
  • As of Q3 2025, Lyra Therapeutics' Depreciation & Amortization (CF) stood at $100000.0, which was up 40000.0% from $200000.0 recorded in Q2 2025.
  • Lyra Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $400000.0 for Q3 2021, and its period low was -$68000.0 during Q3 2023.
  • In the last 5 years, Lyra Therapeutics' Depreciation & Amortization (CF) had a median value of $200000.0 in 2024 and averaged $181421.1.
  • Per our database at Business Quant, Lyra Therapeutics' Depreciation & Amortization (CF) crashed by 12266.67% in 2023 and then soared by 96956.52% in 2024.
  • Quarter analysis of 5 years shows Lyra Therapeutics' Depreciation & Amortization (CF) stood at $278000.0 in 2021, then decreased by 8.27% to $255000.0 in 2022, then plummeted by 58.04% to $107000.0 in 2023, then soared by 68.22% to $180000.0 in 2024, then plummeted by 44.44% to $100000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $100000.0 in Q3 2025, compared to $200000.0 in Q2 2025 and $128000.0 in Q1 2025.